PNC Financial Services Group
CLDI icon

PNC Financial Services Group’s Calidi Biotherapeutics CLDI Stock Holding History

PNC Financial Services Group’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1
Closed -$20 – 4811
2024
Q2 		$20 Hold
1
– – ﹤0.01% 4740
2024
Q1 		$57 Hold
1
– – ﹤0.01% 4662
2023
Q4 		$151 Hold
1
– – ﹤0.01% 4503
2023
Q3 		$333 Buy
+1
New +$1.01K ﹤0.01% 4502

Other funds holding CLDI

CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
CI
CPR Investments Rochester, Michigan $130M AUM 29.56% 1-Year Est. Return
RWI
Red Wave Investments Dillsburg, Pennsylvania $335M AUM 15.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
DIM
Delta Investment Management San Francisco, California $559M AUM 19.86% 1-Year Est. Return
AMH
Apollo Management Holdings New York $7.6B AUM 23.97% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
EWM
Evermay Wealth Management Arlington, Virginia $902M AUM 14.76% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

PNC Financial Services Group's CLDI Position: Q3 2024 in Review

PNC Financial Services Group sold out of Calidi Biotherapeutics (CLDI) in Q3 2024, closing a stake of 1 share — an estimated $20 sold.

PNC Financial Services Group first reported a position in CLDI in Q3 2023 and held it in 4 quarters. The position peaked at $333 in Q3 2023. 20 funds tracked by Wall St. Rank hold CLDI as of Q3 2024.

  • PNC Financial Services Group reported no remaining Calidi Biotherapeutics position as of Q3 2024 after selling out during the quarter.
  • PNC Financial Services Group sold 1 Calidi Biotherapeutics share in Q3 2024, an estimated $20.
  • PNC Financial Services Group first reported a position in Calidi Biotherapeutics in Q3 2023 and held it in 4 quarters.
  • PNC Financial Services Group's Calidi Biotherapeutics position peaked at $333 in Q3 2023.
  • 20 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2024.

Based on PNC Financial Services Group's 13F filing for Q3 2024, filed 8 Nov 2024.